FDA approves Roche ’s Tecentriq in combination with Avastin for people with the most common form of liver cancer
Basel, 2 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received p rior systemic therapy.“We’re excited that today’s approval of Tecentriq in combination with Avastin for unresectable or metastatic hepatocellular carcinoma brings a cancer immunotherapy option to people with this aggressive form of liver cancer,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer ...
Source: Roche Media News - June 2, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq in combination with Avastin for people with the most common form of liver cancer
Basel, 2 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - June 2, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Genentech ’s Tecentriq in Combination With Avastin for People With Hepatocellular Carcinoma
South San Francisco, CA -- May 29, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq ® (atezolizumab) in combination... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 29, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Atezolizumab/Bevacizumab Combination for HCC
The FDA approved atezolizumab in combination with bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Medivir Appoints Yilmaz Mahshid as New CEO
STOCKHOLM, May 26, 2020 -- (Healthcare Sales & Marketing Network) -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that its Board of Directors has appointed Yilmaz Mahshid as the new CEO of the company. Yilmaz Mahshid has long and broad experience f... Biopharmaceuticals, Oncology, Personnel Medivir AB, hepatocellular carcinoma, liver cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 26, 2020 Category: Pharmaceuticals Source Type: news

Liver cancer: Awareness of hepatitis D must be raised
(Universit é de Gen è ve) Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma. They demonstrated that people infected with Hepatitis D have up to three times the risk of developing that particularly aggressive and often fatal liver cancer compared to those infected only with Hepatitis B. These results, to be read in the Journal of Hepatology, plead for systematic screening of Hepatitis D in patients with Hepatitis B. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 18, 2020 Category: International Medicine & Public Health Source Type: news

' Momentous' Data for First-Line Combo in Liver Cancer'Momentous' Data for First-Line Combo in Liver Cancer
The combination of atezolizumab and bevacizumab for the first-line treatment of unresectable hepatocellular carcinoma is set to become the new standard of care for this poor-prognosis cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 14, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New treatment extends lives of people with most common type of liver cancer
For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.Researchers found that a  combination of atezolizumab, an immunotherapy drug that boosts the body ’s natural defenses, and bevacizumab, an anti-angiogenesis drug that inhibits the growth of tumors’ blood vessels, improved overall survival and reduced the risk of death by 42%. It also decreased the risk of the disease worsening by 41%, and the percentage of patients whose cancer shrank or disappeared more than doubled.R...
Source: UCLA Newsroom: Health Sciences - May 13, 2020 Category: Universities & Medical Training Source Type: news

Atezolizumab-Bevacizumab Beats Sorafenib in Liver Cancer
WEDNESDAY, May 13, 2020 -- Atezolizumab plus bevacizumab improves survival outcomes versus sorafenib in patients with unresectable hepatocellular carcinoma, according to a study published in the May 14 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 13, 2020 Category: Pharmaceuticals Source Type: news

New treatment extends lives of people with most common type of liver cancer
(University of California - Los Angeles Health Sciences) For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 13, 2020 Category: Cancer & Oncology Source Type: news

Mesothelioma Drug Combination Continues to Show Promise
Pharmaceutical giant Bristol Myers Squibb continues to tout its immunotherapy combination of Opdivo and Yervoy for first-line treatment of patients with pleural mesothelioma cancer. Bristol Myers Squibb recently announced that overall survival “significantly improved” when the combination was measured against standard chemotherapy in a randomized, phase III clinical trial of previously untreated mesothelioma patients. Its announcement was based on a pre-specific interim analysis conducted by the Data Monitoring Committee, a clinical study organization independent of Bristol Myers Squibb. The study is being conducted at...
Source: Asbestos and Mesothelioma News - May 4, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Thermal Ablation for Hepatocellular Carcinoma: What's New Thermal Ablation for Hepatocellular Carcinoma: What's New
Get up-to-date on the latest developments and new advancements in the use of thermal ablation for the treatment of hepatocellular carcinoma.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 4, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Medivir Receives Positive Opinion on Orphan Medicinal Drug Designation by the European Medicines Agency for MIV-818
STOCKHOLM, April 30, 2020 -- (Healthcare Sales & Marketing Network) -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has received positive opinion from the Committee for Orphan Medicinal Products on orphan medicinal product designation in t... Biopharmaceuticals, Oncology, Regulatory Medivir, hepatocellular carcinoma, liver cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 30, 2020 Category: Pharmaceuticals Source Type: news

New study indicates exercise can help prevent liver cancer
(Elsevier) Liver cancer is the fourth most common cause of cancer death worldwide and is growing rapidly due to the 'diabesity pandemic.' A new study reported in the Journal of Hepatology, published by Elsevier, provides strong evidence that voluntary exercise could help prevent the most common type of liver cancer, hepatocellular carcinoma, and identifies the molecular signaling pathways involved. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 14, 2020 Category: Cancer & Oncology Source Type: news

Sugar, Fat, Alcohol … What’s Worse for the Liver?
This webinar will investigate the increasing mortality rates of liver disease in the UK associated with obesity and the excess consumption of alcohol. It will give an overview of non-alcoholic fatty liver disease (NAFLD), which is now the most common  of liver disease affecting an estimated 25-30% of adults and 10% of children in the UK and worldwide. Both NAFLD and alcohol-related fatty liver can progress to severe liver disease including fibrosis, cirrhosis and hepatocellular carcinoma. The roles of genetics, obesity and dietary patterns i n the development and progression of liver disease will be discussed. In the c...
Source: The Nutrition Society - April 9, 2020 Category: Nutrition Authors: Jade Mitchell Source Type: news